Hepatitis A – (HepA)
Recommended Age Range:
12–23 months (two doses, six months apart)
Common Side Effects:
Soreness, headache, appetite loss
Research & Testing History:
Trials showed >95% seroconversion after 2 doses; licensed 1995.
Use History:
Recommended since 1995
Trial Size:
5 clinical trials of ~4,300 infants & clinical trial of ~10,000 children & adults
Years on Schedule:
~30 years
Known Safety Concerns:
Rare allergic reactions
Ingredients:
- Havrix: Inactivated hepatitis A virus; adjuvant: aluminum hydroxide; stabilizers: amino acid supplement, phosphate-buffered saline solution, polysorbate 20; residuals: proteins from MRC-5 human cells, formalin, neomycin sulfate
- Vaqta: Inactivated hepatitis A virus; adjuvant: amorphous aluminum hydroxyphosphate sulfate; stabilizers: sodium borate, sodium chloride; residuals: proteins and DNA from MRC-5 human cells, bovine albumin, formaldehyde, neomycin